FY2024 EPS Estimates for Opus Genetics Cut by HC Wainwright

Opus Genetics, Inc. (NASDAQ:IRD) – HC Wainwright decreased their FY2024 earnings per share estimates for Opus Genetics in a report released on Wednesday, November 13th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($1.22) for the year, down from their prior estimate of ($1.11). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.11) per share. HC Wainwright also issued estimates for Opus Genetics’ Q4 2024 earnings at ($0.34) EPS, FY2025 earnings at ($1.03) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.53) EPS and FY2028 earnings at ($0.23) EPS.

Opus Genetics (NASDAQ:IRD) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.01. The company had revenue of $3.87 million for the quarter, compared to analyst estimates of $1.17 million. Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 63.65%.

Opus Genetics Trading Down 1.9 %

Opus Genetics stock opened at $1.06 on Friday. Opus Genetics has a 12-month low of $1.06 and a 12-month high of $3.40.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.